ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Geriatric Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,442Medicare Part D Prescriptions Filled, Including Refills

Rank: 18 out of 29

$589K Total Retail Price of All Prescriptions

Rank: 11 out of 29

408 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
18% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

17% of this provider’s 408 patients filled at least one prescription for a schedule three drug, compared to an average of 13%.

Risky Drugs to Seniors

1% of this provider’s 8,686 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$62 was the average price of a prescription from this provider, compared to $52 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
HYDROCODONE-ACETAMINOPHEN 313 290 S3 1 7
SIMVASTATIN 304 284 2 4
OMEPRAZOLE 300 282 3 8
ZOLPIDEM TARTRATE 298 252 4 30
PRAVASTATIN SODIUM 269 255 5 18
POTASSIUM CHLORIDE 235 233 6 6
AMLODIPINE BESYLATE 205 188 7 5
ATORVASTATIN CALCIUM 197 185 8 25
HYDROCHLOROTHIAZIDE 172 165 9 20
LEVOTHYROXINE SODIUM 170 158 10 1
FUROSEMIDE 168 168 11 3
SYNTHROID 157 144 12 52
RAMIPRIL 155 139 13 90
GLIMEPIRIDE 155 151 13 65
METOPROLOL SUCCINATE 140 140 15 16
CRESTOR 129 115 16 62
METOPROLOL TARTRATE 129 118 16 15
LISINOPRIL 124 116 18 2
ALENDRONATE SODIUM 119 119 19 26
MELOXICAM 115 103 20 36
NEXIUM 110 89 21 47
GABAPENTIN 108 99 22 10
ALLOPURINOL 100 100 23 40
FLUTICASONE PROPIONATE 95 85 24 43
CITALOPRAM HBR 82 77 25 11
ATENOLOL 79 72 26 23
TRAMADOL HCL-ACETAMINOPHEN 78 70 27 170
ESCITALOPRAM OXALATE 77 73 28 37
TRIAMTERENE-HCTZ 77 77 28 48
TIZANIDINE HCL 74 66 30 174
DIOVAN 73 64 31 35
ZETIA 71 47 32 125
CLONIDINE HCL 70 70 33 53
AMLODIPINE BESYLATE-BENAZEPRIL 62 62 34 119
TRAMADOL HCL 62 62 34 24
PREDNISONE 62 57 34 41
ADVAIR DISKUS 62 54 34 68
TAMSULOSIN HCL 61 56 38 31
MIRTAZAPINE 61 61 38 13
CYMBALTA 61 48 38 29
GEMFIBROZIL 59 49 41 116
METFORMIN HCL 59 47 41 19
EVISTA 58 57 43 55
LIPITOR 58 57 43 158
TRIAMTERENE-HYDROCHLOROTHIAZID 57 56 45 154
LOSARTAN POTASSIUM 52 51 46 28
DILTIAZEM 24HR CD 52 47 46 109
METFORMIN HCL ER 51 49 48 129
ONGLYZA 51 49 48 202
WARFARIN SODIUM 51 45 48 14
DILTIAZEM ER 50 37 51 113
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 29, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.